Repligen Corp.
RGEN
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
78.2% downsideOvervalued by 78.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.31 Billion |
|---|---|
| Enterprise Value | $8.43 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.87 |
| Beta | 1.06 |
| Outstanding Shares | 56,354,000 |
Return
| Return on Equity | 2.44% |
|---|---|
| Return on Assets | 1.75% |
| Return on Invested Capital | 1.21% |
Valuation & Multiples
| P/E Ratio | 161.81 |
|---|---|
| PEG | 376.9 |
| Price to Sales | 10.78 |
| Price to Book Ratio | 3.79 |
| Enterprise Value to Revenue | 11.04 |
| Enterprise Value to EBIT | 248.46 |
| Enterprise Value to Net Income | 164 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.34 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 182.60% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.67%▼ 110.69% |
|---|---|
| Total Invested | $435.67M▼ 94.38% |
| Investors Holding | 67▼ 384.00% |
ESG Score
No data
About Repligen Corp.
CEO: Anthony Hunt Relevant Senate Committees
This committee's analysis and scoring of tax legislation directly influence corporate tax structures and financial obligations for all companies, including Repligen.
Tax policy directly impacts corporate profitability, investment, and valuation. Trade policy can affect supply chains, and entitlement spending (e.g., Medicare pricing) heavily influences the market for biopharmaceutical products, thus impacting Repligen's customers.
This committee's oversight of the FDA (which regulates biological products and their manufacturing components) and NIH (which funds biotech research) is critically important. Labor laws also directly affect RGEN's operations.
Intellectual property protection (patents, trade secrets) is fundamental to a biotech manufacturing company like Repligen. Antitrust concerns could also arise in the event of significant M&A activity.